Figure 9.
Interactions between MEK, c-Myc, c-Fos and growth factors. The effects of EGF and TNF-alpha are mediate via the MEK-pathway. Selumetinib and other MEK/ERK inhibitors are being primarily developed and studied for cancer treatment. However, the role of the MEK/ERK-pathway in endometriosis suggests that these therapeutic strategies may lend themselves equally well to this disease.